Skip to main content
Active Surveillance Patients International

De-Intensifying Active Surveillance: Can Some Men on Active Surveillance Safely Do Less?

 

Can some men on Active Surveillance safely reduce testing over time?

In this ASPI educational session, Dr. Michael S. Leapman, a urologic oncologist at Yale Medicine, discusses whether some men on Active Surveillance may be able to safely stretch out monitoring intervals while still keeping prostate cancer carefully watched.

Dr. Leapman explains how age, cancer grade, PSA trends, PSA density, MRI findings, biopsy results, biomarkers, and overall health may help guide a more personalized monitoring plan. He also discusses why the early years of Active Surveillance are important for confirming that the cancer has been accurately profiled — and when stable findings may support doing less over time.
 


 

What De-Intensifying Active Surveillance Can Mean

Active Surveillance is not refusing treatment. It means watching low-risk or selected intermediate-risk prostate cancer closely, with the intention of treating it if meaningful changes occur.

In this session, Dr. Leapman discusses three practical questions: Can testing be done less often? Can monitoring be reduced after years of stability? And can less invasive tools, such as MRI or biomarkers, help reduce the need for biopsy?

He emphasizes that de-intensification should be personalized. Grade Group 1 prostate cancer is the clearest area where reducing monitoring may be possible for some men, while Grade Group 2 requires more careful selection and discussion.

Download the slides from Dr. Leapman’s presentation here.

Key takeaways include:

  • Stable findings over time may allow some men to stretch out testing intervals
  • PSA testing, MRI, and biopsy each provide different information
  • A stable MRI and low PSA density may help support longer intervals between biopsies
  • MRI is useful for deciding when to biopsy, but it has not fully replaced biopsy
  • A negative follow-up biopsy can be a reassuring sign
  • Age, competing health risks, and personal anxiety should be part of the monitoring plan
  • Genomic tests and newer biomarkers may eventually help guide de-intensification, but more research is needed

 


 

Watch the Discussion

Chapters

  • 00:00 – Welcome, ASPI updates, and PCRI conference note
  • 05:26 – Introduction to Dr. Michael S. Leapman
  • 07:47 – Presentation begins
  • 08:12 – Can we de-intensify Active Surveillance?
  • 14:52 – What Active Surveillance means
  • 17:05 – Long-term evidence and the PROTECT study
  • 21:35 – Monitoring tools: PSA, MRI, and biopsy
  • 24:21 – Three ways to safely do less testing
  • 26:38 – Who may be able to scale back monitoring
  • 30:54 – MRI and stretching time between biopsies
  • 33:43 – Genomic testing and Decipher
  • 35:50 – Early years, years 2–5, and the five-year mark
  • 38:42 – What we know and what still needs research
  • 44:59 – Q&A begins
  • 1:17:57 – Anxiety, less testing, and personalizing the monitoring plan

 


 

About the Speaker

Dr. Michael S. Leapman is a urologic oncologist at Yale Medicine and Clinical Program Leader of the Prostate & Urologic Cancers Program at Yale Cancer Center. His work focuses on prostate cancer, early detection, biomarkers, imaging, treatment effectiveness, and more personalized approaches to prostate cancer care.
 


 

Learn More About Active Surveillance

Share this: